Inclusion Formation and Toxicity of The ALS Protein RGNEF and Its Association with the Microtubule Network

Sonja E. Di Gregorio¹, Kathryn Volkening² and Michael J. Strong² & Martin L. Duennwald¹

¹ Department of Pathology and Laboratory Medicine, University of Western Ontario, London Ontario, Canada
² Clinical Neurological Sciences, University of Western Ontario, London Ontario, Canada

Correspondence: martin.duennwald@schulich.uwo.ca

Abstract: The Rho guanine nucleotide exchange factor (RGNEF) protein encoded by the ARHGEF28 gene has been implicated in the neurodegenerative disease amyotrophic lateral sclerosis (ALS). Biochemical and pathological studies have shown that RGNEF is a component of the hallmark neuronal cytoplasmic inclusions in ALS-affected neurons. Additionally, a heterozygous mutation in ARHGEF28 has been identified in a number of familial ALS (fALS) cases that may give rise to one of two truncated variants of the protein. Little is known about the normal biological function of RGNEF or how it contributes to ALS pathogenesis. To further explore RGNEF biology we have established and characterized a yeast model and characterized RGNEF expression in several mammalian cell lines. We demonstrate that RGNEF is toxic when overexpressed and forms inclusions. We also found that the fALS-associated mutation in ARHGEF28 gives rise to an inclusion-forming and toxic protein. Additionally, through unbiased screening using the split-ubiquitin system, we have identified RGNEF interacting proteins, including two ALS-associated proteins. Functional characterization of other RGNEF interactors identified in our screen suggest that RGNEF functions as a microtubule regulator. Our findings indicate that RGNEF misfolding and toxicity may cause impairment of the microtubule network and contribute to ALS pathogenesis.

Keywords: RGNEF; ALS; yeast model; protein misfolding; microtubules; neurodegeneration

Introduction

Amyotrophic lateral sclerosis (ALS) is a heterogeneous neurodegenerative disease caused by loss of upper and lower motor neurons in the brain and spinal cord (Hardiman et al., 2017). ALS can be grouped into sporadic ALS (sALS), i.e. without any family history, which accounts for ~90% of all ALS cases, and familial ALS (fALS) with a family history of ALS, which accounts for ~10% of all ALS cases (Chen et al., 2013). Despite considerable efforts, the molecular mechanisms underpinning the disease remain and there are no satisfactory treatments for ALS. Since the discovery of ALS mutations in SOD1, more than twenty-six genes have been identified as causative for fALS (Srinivasan and Rajasekaran, 2020, Gitler and Fryer, 2018). Many of these proteins are involved in RNA metabolism, including C9orf72, Tar DNA binding protein (TDP-43), and Fused in eSarcoma (FUS) (Gitler and Fryer, 2018, Srinivasan and Rajasekaran, 2020).

Protein misfolding is a global hallmark of neurodegenerative disorders, including ALS (Parakh and Atkin, 2016, Soto and Estrada, 2008, Soto, 2003). A protein is considered to be misfolded when its soluble, native three-dimensional conformation is compromised leading to aberrant changes in structure and function. Misfolded ALS proteins, such as TDP-43, FUS, and SOD1, often mislocalize and form pathological aggregates and inclusions in the cytoplasm of motor neurons termed neuronal cytoplasmic inclusions (NCIs) (Saberi et al., 2015). Genetic mutations can severely increase the propensity of ALS proteins to misfold as demonstrated for FUS and TDP-43 and many other proteins (Kryndushkin and Shewmaker, 2011, Redler and Dokholyan, 2012, Patel et al., 2015).
However, most sALS cases are not linked to any known mutations. Environmental insults, such as changes in pH and exposure to toxic chemicals or excessive oxidative stress, can lead to protein misfolding that may contribute to neurodegeneration in ALS (Cannon and Greenamyre, 2011, Barber et al., 2006). Finally, the highest risk factor for most neurodegenerative diseases is advanced age, indicating that the physiological changes associated with aging contribute to disease-related protein misfolding (Kikis et al., 2010).

The Rho guanine nucleotide exchange factor (RGNEF) protein has recently been implicated in ALS (Volkening et al., 2010, Keller et al., 2012, Droppelmann et al., 2013b). RGNEF is a 191kDa, RNA binding protein encoded by the ARHGEF28 gene in humans. RGNEF belongs to the family of Diffuse B-cell lymphoma (DbI) GEFs and contains a Leucine-rich region at its amino-terminus, a Plekstrin homology domain (PH), a cysteine-rich Zink-finger domain, FAK (focal adhesion kinase) binding domain, microtubule binding domain, and an nuclear localization signal (NLS, (Tavolieri et al., 2019). The normal cellular function of RGNEF is not well understood; however, it has been linked to multiple disorders in addition to ALS, including cancer, e.g. colorectal and ovarian cancer (Kleinschmidt et al., 2019, Cheung et al., 2017, Wu et al., 2003, Miller et al., 2012, Yu et al., 2011).

Biochemical and pathological studies implicate RGNEF as an ALS protein, yet how the mechanisms by which it contributes to ALS pathogenesis remain unknown. A heterozygous mutation in exon 6 of ARHGEF28 has been identified in a small number of fALS cases (Droppelmann et al., 2013b). These finding were supported by Ma et al., 2014, who detected the same RGNEF mutation in two additional ALS cases. Both these cases were heterozygous for the ARHGEF28 mutations, and both identified patients showed similar ALS symptoms, including bulbar onset. These patients did not have a family history of ALS and did not possess overlapping mutations in either SOD1 or C9orf72 as the previously identified ALS patients (Ma et al., 2014). The deletion of a single nucleotide is predicted to lead to either a frameshift mutation that gives rise to a premature stop codon resulting in a severely truncated RGNEF protein or may also cause splicing errors in exon 6 of ARHGEF28 causing exon skipping that would generate a severely truncated RGNEF protein with a slightly different sequence from that of the first proposed mutation (Droppelmann et al., 2013b, Farhan et al., 2017) (Farhan et al., 2017).

RGNEF has been found to localize to hallmark NCIs in ALS patient spinal cord motor neurons, where RGNEF co-localizes with other RNA binding ALS proteins such as TDP-43, FUS, and C9orf72 (Keller et al., 2012, Droppelmann et al., 2013a). Additionally, RGNEF co-localizes with markers of protein degradation, such as p62 and ubiquitin (Keller et al., 2012, Droppelmann et al., 2013a). The only variant of ALS that did not show RGNEF in NCIs tested so far were ALS cases bearing SOD1 mutations.

Additionally, metabolic stress induces formation of micronuclei, small nuclear fragments in cultured cell models (Schmid, Kirsch-Volders et al., 1997). These structures are also found in the brains and spinal cords of ALS patients. TDP-43 inclusions in micronuclei co-localize with RGNEF and may be released into the cytoplasm (Droppelmann et al., 2019). The Leucine-rich region of RGNEF is critical for interaction with TDP-43 and localization to micronuclei. In addition, RGNEF regulates neurofilaments via binding to the mRNA encoding low molecular weight neurofilaments. Human RGNEF destabilizes neurofilament mRNA and over expression of RGNEF reduced protein levels of neurofilament in stable cell lines (Droppelmann et al., 2013a).

In sum, all these findings document that RGNEF contributes to ALS pathogenesis, yet the precise underlying cellular mechanisms remain mostly unclear. Here, we established and characterized a yeast model and employed cultured neuronal cells to explore RGNEF misfolding, toxicity, and its interactions with major cellular pathways. Our results indicate that RGNEF can undergo toxic misfolding and that it interacts with the microtubule network, which may contribute to neurotoxicity and to neurodegeneration in ALS.

Results

We first established and characterized an RGNEF yeast model. Figure 1A shows schematic representations of the domain structure of wild type and the truncated RGNEF variants used in our
Upon expression in yeast, we found that the expression of full length wild type RGNEF reduced the growth of yeast cells by ~50% of control cells (p<.05, Figure 1B and C). Interestingly, the construct lacking the amino-terminus, but containing the GEF domain of RGNEF (∆Cterm) was more toxic than wild type RGNEF, reducing growth by over 50% (p<.05). Additionally, expression of construct lacking the amino-terminal Leucine-rich region (∆Leu) is highly toxic in yeast, showing over 90% reduction of growth (p<.01) (Figure 1B and C). All other truncations tested here did not exhibit a growth defect in yeast.

Figure 1. RGNEF toxicity in yeast. A RGNEF WT and domain-deleted truncations are illustrated. B Yeast growth assay of RGNEF WT and mutants. Cells were plated on non-inducing and inducing agar plates in one to five serial dilutions to observe the growth phenotype associated with expressing each variant (left). C Results as shown in B were quantified normalized to growth of the control cells (vector). Error bars represent standard deviation of the mean. One Way Analysis of Variance, Tukey Post Hok shows statistical significance of reduced growth for full length wild-type RGNEF (P<.05), ∆Cterm (P<.05), and ∆Leu (P<.01) compare to controls. Error bars represent standard deviations.

We monitored subcellular localization of RGNEF in yeast by expressing yellow fluorescent protein (YFP) carboxy-terminal fusion to full length RGNEF (RGNEF-YFP) and its truncated variants lacking specific functional domains (Figure 2A). All truncations and wild type RGNEF YFP-fusions
form fluorescent foci in the cytoplasm of yeast cells, albeit to different proportions of cells (Figure 2B). Full length wild type RGNEF-YFP is found mostly localized in foci, however, not exclusively, with some cells displaying a fully diffuse signal, whereas other cells contain a single large or several small fluorescent foci. The bar graph in Figure 2B represents the proportion of cells containing large foci (black bar) as a percentage over the total number of cells. The construct lacking the carboxy-terminus (∆Cterm) showed less foci than wild type and the construct lacking the amino-terminal Leucine-rich domain (∆Leu) showed a fraction of cells with foci similar to WT. Figure 2c documents full length wild-type RGNEF expression by western blot analysis.

Figure 2. RGNEF-YFP localization in yeast. A RGNEF-YFP (wild-type full length and truncated variants) localization and aggregation was observed using fluorescence microscopy in live yeast cells. B Bar graph represents the quantification of data as shown in A as percentile of cell containing inclusions. C RGNEF expression is shown by western blot analysis. Error bars represent standard deviations.

Figure 3A shows schematic representations of the two ALS variants that are predicted to arise from mutations in ARHGEF28 in fALS compared to the full length wild type protein and the leucine-rich region of RGNEF alone. We expressed in yeast these RGNEF variants, 259 and 319 named here after their respective amino acid lengths. Toxicity was observed when the larger truncation, 319, was expressed in yeast and to a lesser extent for the short variant, 259 (Figure 3B and C). Carboxy-terminally YFP-tagged constructs of 259 and 319 were utilized to examine the subcellular localization. When expressed in yeast we found that both mutants showed mostly diffuse signals with a small subset of cells showing a single large inclusion (Figure 3 E and F).
Figure 3. Yeast model of predicted ALS-associated RGNEF variants. A Schematic presentation of full length wild-type RGNEF and truncated ALS-associated constructs. The truncations are named according to their predicted amino acids lengths. B Yeast growth assay of RGNEF WT and predicted truncations. C Quantification of data as shown in B. D Localization predicted ALS-associated RGNEF variants fused to YFP by fluorescence microscopy. E Quantification of the fluorescent microscopy as show in D as percentages of cells containing fluorescent foci. Error bars represent standard deviations.

Overexpression of RGNEF and the truncations lacking the carboxy terminus (ΔCterm) or the Leucine-rich region (ΔLeu) upon transient transfection of expression plasmids in HEK 293 cells corroborated the growth defects observed in yeast. Luciferase-based viability assays revealed toxicity in cells expressing the full length wild type RGNEF and ΔCterm and ΔLeu as compared to vector
only control (p<.05) (Figure 4A). Additionally, localization of full length RGNEF and ΔCterm and ΔLeu in HEK 293 cells was evaluated using carboxy-terminally GFP-tagged fusions. Fluorescence microscopy revealed a mostly diffuse localization of wild type RGNEF, ΔCterm, and ΔLeu expressing cells with a small proportion of cells containing fluorescent foci (Figure 4B).

**Figure 4.** RGNEF toxicity and localization in mammalian cells. A Transfection of HEK 293 cells with DsRED control and RGNEF WT, ΔCterm, and ΔLeu constructs. Following transfection, cell viability was measured by lucipherase assay and quantified. B Fluorescence microscopy of GFP-tagged RGNEF constructs transfected into HEK 293, i) full length wild-type RGNEF and ii) DsRed vector control (4x magnification, iii) RGNEF WT iv) DsRed expressing vector control, ΔCterm overexpression and v) ΔLeu overexpression (20x magnification) C Endogenous RGNEF localization is monitored by immunofluorescence microscopy in HeLa (i), Neuro-2a (ii), and SN56 cells (iii) by immune-fluorescence microscopy. Error bars represent standard deviations.
We also examined the subcellular localization of endogenously expressed RGNEF in three mammalian cell lines by immunofluorescence microscopy. For these experiments we used HeLa cells (human), and the neuronal cell lines Neuro-2a and SN-54 (both mouse, Figure 4C). In HeLa cells, RGNEF (green) is found localized in both the nucleus (blue) and cytosol, appearing in a speckled pattern (Figure 4C i). The same pattern is observed in partially differentiated Neuro-2a (Figure 4C ii) and SN-54 cells (Figure 4C iii) where RGNEF is found in the nucleus and the cytosol, and along the entire neurite extensions (Figure 4C, bottom row, inset), indicating that in the absence of any cellular stress and at endogenous expression levels RGNEF does not normally form inclusions.

We next tested whether exposure to cellular stress modulates RGNEF misfolding and toxicity in yeast. We used MG132 (a proteasome inhibitor) or radicicol (an Hsp90 inhibitor) to induce protein quality control stress, hydrogen peroxide to induce oxidative stress, and tunicamycin or DTT to induce endoplasmic reticulum (ER) stress (Figure 5). Cells containing the indicated small molecules were evaluated by growth assays to assess RGNEF-dependent sensitivity or resistance to cellular stress. Figure 5A shows untreated control on non-inducing (and inducing conditions (Figure 5A i and ii). Figure 5B-E shows that the presence of MG132, hydrogen peroxide, and tunicamycin exacerbated the growth defect associated with full length wild type RGNEF expression (all p<.01).
Figure 5. RGNEF toxicity under cellular stress. A Yeast growth assay of yeast cells under non-inducing (i) and inducing conditions (ii) for the expression of full length wild-type and truncated RGNEF variants. B. Yeast growth assay of cells expressing full length wild-type and truncated RGNEF variants under inducing conditions containing i) 50uM MG132 ii) 100uM H2O2 and iii) 25uM Radicicol. C Quantification of the growth assays as show in C normalized data to the vector control, i) 50uM MG132, ii) 100uM hydrogen peroxide, iii) 25uM radicicol. D Yeast growth assay of cells expressing full length wild-type and truncated RGNEF variants containing i) 0.1 µg/ml tunicamycin, and ii) 5mM DTT. E Quantification of the growth assay as shown in D normalized data to vector controls, i) 1µg/ml Tunicamycin and ii) 5mM DTT. Error bars represent standard deviations.

To evaluate RGNEF inclusion formation in the presence of cellular stress, we employed mouse Neuro-2a cells and monitored the localization of endogenously expressed RGNEF by immunofluorescence microscopy. When Neuro-2a cells were treated with AZC (Figure 6A ii), MG132 (Figure 6A iii), and hydrogen peroxide (Figure 6A v), RGNEF localization was unaltered compared
to untreated cells (Figure 6A i). In cells treated with radicicol, RGNEF aggregation appeared almost completely diffuse (Figure 6A iv). These results indicate the formation of large cytoplasmic inclusions might depend on its over-expression as noted before for other ALS proteins.

Figure 6. RGNEF localization under cellular stress in Neuro-2A cells. A Endogenous RGNEF is visualized by immuno-fluorescence microscopy in untreated and stress treated conditions in semi-differentiated Neuro-2A cells, i) untreated, ii) 2mM AZC, iii) 15uM MG132, iv) 25µM radicicol and v) 250µM hydrogen peroxide. Error bars represent standard deviations.

The split-ubiquitin system is an in vivo assay that detects protein-protein interaction in yeast by simple growth assays (Johnsson and Varshavsky, 1994, Lehning, 2002). Using the split amino and carboxyl-terminal halves of ubiquitin fused to a bait and prey protein respectively, the split-Ubiquitin assay detects both stable and transient interactions (Johnsson and Varshavsky, 1994). Furthermore, single amino acid residue substitutions within the NUb-bait fusions allow for additional assessment of the strength of the interaction (Muller and Johnsson, 2008) (Figure 7A). RUra3 serves as a reporter in the assay, where interactions between bait and prey fusions lead to the exposure of the degron (R) and mediates degradation of the Ura3 protein which allows yeast to grow on media containing 5FOA, but not on media lacking uracil as illustrated in Figure 7A.

In this study, RGNEF was used as the prey protein fused to the C-terminal half of ubiquitin (RGNEF Cub, Figure 7A). A growth assay was performed to examine the proper expression of the RGNEF-CUb-RUra3p (RGNEF-CRU) fusion constructs. DNAJBI-CUb-RUra3p (DNAJBI-CRU) served as a non-toxic control. The split-ubiquitin constructs are under transcriptional control of the CUP1 promotor, whose activity increases with increasing Cu2+ ion concentrations in the media. The expression of RGNEF-CUb-RUra3p is mildly toxic compared to DNAJBI-CUb-RUra3p but both fusions allowed growth on media lacking uracil, which is a prerequisite for the split-ubiquitin assay (Figure 7B).
Figure 7. **RGNEF Split-Ub experiments.** B Growth assays of yeast cells expressing DNAJB1-CRU (control) and RGNEF-CRU on inducing and non-inducing media. C Split-Ub interactions assays with RGNEF-CRU and TDP-43-NUb (left), RGNEF-NuB (middle), and PGK1-NUb (right). D List of all candidate RGNEF interactors identified in a split-Ub screen using RGNEF-Cub-CRU as prey and a human NubG library as bait.

In a directed split-ubiquitin experiment we co-expressed RGNEF-Cub-RUra3p with NUb-I/A/G-TDP-43, NUB-I/A-/RGNEF or UB-I/A-/PGK1. TDP-43 co-localizes with RGNEF in NCIs in ALS motor neurons and in fly models. Thus, TDP-43 served as a positive control for RGNEF.
RGNEF was also tested for its capacity to form multimers. PGK1 is a human metabolic enzyme and is not expected to interact with RGNEF (negative control). Poor growth was observed on plates lacking uracil and growth was observed on 5FOA plates when TDP-43 and RGNEF constructs were co-expressed, confirming that these two proteins interact. We also found that RGNEF can interact with other RGNEF molecules, albeit to a lesser extent than with TDP-43. PGK1 did not interact with RGNEF, indicating specificity for the TDP-43 and homomeric RGNEF interactions. These experiments show that the split-ubiquitin can detect RGNEF interactions.

The RGNEF-Cub-RUra3 fusion protein was then screened against the human cDNA-based Nub-G fusion library and over 25 novel interactors with RGNEF were identified (Figure 7D). The largest functional group within these interactors were microtubule regulators, including the protein tau, which has been speculated to participate in ALS pathogenesis. While the RGNEF contains a predicted microtubule binding domain, this is, to our knowledge, the first experimental evidence of an interaction between RGNEF and the microtubule network (van Horck et al., 2001). An additional protein associated with ALS, Sigmar-1, was also identified as an RGNEF interacting protein.

To further explore the novel finding that RGNEF interacts with the cellular microtubule network, we employed our yeast model and assessed genetic interaction between viable microtubule regulator gene deletions and RGNEF (Figure 8A). We found that deletion of several of these gene deletions increased RGNEF toxicity. Kip2 is a kinesin-related motor protein involved in mitotic spindle positioning and stabilizing microtubules (Miller et al., 1998). Expression of RGNEF in the absence of KIP2 enhanced RGNEF toxicity compared to wild type cells (Figure 8A and B, p<.05). ASE1 is a microtubule associated family member (MAP) required for spindle elongation and stabilization (Schuyler et al., 2003). RGNEF toxicity is also enhanced in yeast strains bearing deletions of ASE1(Figure 8A iii and B, p<.05). VIK1 is a protein that forms kinesin-14 heterodimeric motor with KAR3 and localizes KAR3 at the mitotic spindle poles (Allingham et al., 2007). Expression of RGNEF in yeast cells bearing deletions for VIK1 (Figure 8A, iv and B, p<.01) or KAR3 (Figure 8A v and B, p<.01) was non-viable, indicating a strong synthetic toxicity and a strong genetic interaction. BEM3 is a Rho GTPase activating protein (RhoGAP) involved in actin cytoskeleton organization (Zheng et al., 1993). Deletion of this gene increases RGNEF toxicity to a lesser extent then the gene deletions tested above, indicating a stronger genetic interactions between RGNEF and microtubule associated genes than with actin regulating genes (Figure 8A v and B, p<.05).
Figure 8. Genetic interaction between RGEN and genes expressing microtubule-associated genes.  
A Growth assay of yeast cells expressing full length wild-type RGNEF in a wild-type yeast strain and microtubule-associated gene deletion strains: i) WT strain, ii) ∆Kip2, iii) ∆Ase1, iv) ∆Vik1, v) Kar3, and vi) ∆BEM.  
B Quantification of growth assay as shown in A.  
C Growth assay of yeast cells expressing wild-type RGNEF in a wild-type yeast strain grown on inducing media containing i) 500 nM Colchicine and ii) 500 nM Nocodazole.  
D Quantification of growth assays as shown in C. Error bars represent standard deviation.  
E Immunofluorescence microscopy of partially differentiated Neuro-2a cells detecting endogenous RGNEF: i) untreated cells, ii) 500 nM Colchicine and iii) 500 nM Nocodazole. Error bars represent standard deviations.
Colchicine, which binds monomeric tubulin and prevents polymerization, and nocodazole, which binds to tubulin polymers and causes de-polymerization, were used to disrupt the microtubules (Leung et al., 2015, Hoebeke et al., 1976). Yeast cells grown on plates containing either small molecule show increased RGNEF toxicity (Figure 8C i-ii and D). In Neuro-2a cells, treatment with colchicine and, to a lesser extent nocodazole, induce large cellular foci of endogenous RGNEF as shown by immunofluorescence microscopy (Figure 8E).

Discussion

RGNEF is a multidomain protein with a combination of a GEF and RNA binding domain that is unique within the human proteome, together with many other functional domains, yet its basic biological function is just starting to be clarified (Cheung et al., 2017). It has also been implicated in a number of diseases, including cancer and neurodegenerative diseases, particularly in ALS (Yu et al., 2011, Masia-Balague et al., 2015, Ma et al., 2014, Kleinschmidt et al., 2019, Keller et al., 2012, Droppelmann et al., 2014, Droppelmann et al., 2013a, Droppelmann et al., 2013b, Balikova et al., 2010). RGNEF is similar to some of the other common ALS-associated proteins, such as TDP-43 and FUS, as it binds RNA and localizes to pathological NCIs (Volkening et al., 2010, Droppelmann et al., 2013b, Droppelmann et al., 2013a, Keller et al., 2012). For TDP-43, FUS and other ALS-associated proteins, there is a marked misfolding event that occurs in the highly disordered domains, which either corresponds with, is caused by, or precipitates, their localization into NCI. Of note, RGNEF does not contain such a prion-like domain as defined before and the mechanisms underlying RGNEF misfolding and aggregation have been unclear (Gitler and Shorter, 2011). Our data from a novel RGNEF yeast model and mammalian cells document that RGNEF indeed can misfold and form cytosolic inclusions independent of other ALS proteins. We also found that RGNEF misfolding and inclusion formation is toxic to cells. Our genetic and split-ubiquitin results further confirm TDP-43 protein as interactors of RGNEF and shed light on a previously unknown function of RGNEF as a possible microtubule interactor and regulator.

To explore RGNEF, we established a novel yeast model. Similar studies in yeast have delivered profound insights into basic mechanisms of protein misfolding and the dysfunction of key cellular pathways associated with both normal cell function and disease, especially neurodegenerative disorders, such as ALS (DiGregorio and Duennwald, 2018, van Ham et al., 2009, Tenreiro and Outeiro, 2010, Tenreiro et al., 2017, Tenreiro et al., 2013). Compared to most other known ALS proteins, RGNEF is relatively understudied, possibly because RGNEF is challenging to study as it is a large complex protein with many functional domains and extremely difficult to clone, express and purify. Our yeast model allows for relatively quick assessment of basic biological characteristics of RGNEF and its possible role in ALS.

Our experiments reveal that expression of wild type full length RGNEF is toxic in yeast. We further demonstrate that the GEF domain is required but not sufficient for this toxicity. This RGNEF toxicity pattern was confirmed in mammalian cells overexpressing RGNEF and its truncations. Analysis of RGNEF localization and aggregation reveals that wild type full length RGNEF and all truncations that contain the GEF and RNA binding domains create inclusions in the cytosol, which is a hallmark of misfolded proteins, such as TDP-43 and FUS. Our results thus indicate that RGNEF can form inclusions, plausibly due to misfolding, and can be toxic to cells. Our results point to a key role of the GEF domain in RGNEF toxicity but the exact mechanisms by which the individual domains contribute to RGNEF toxicity needs to be addressed in future experiments.

The predicted fALS-associated truncation of RGNEF (319) is toxic in yeast, whereas the leucine-rich domain alone is not toxic. The fALS-associated truncation 319 forms inclusions, indicating that the extended regions at the carboxy-terminus of the Leucine-rich domain, which is mostly intrinsically disordered, drives aggregation (Supplemental Figure 1A and B). Of note, these RGNEF truncations have not been detected in post-mortem ALS tissue to date and their potential role in ALS pathogenesis remains unclear. Our results indicate that RGNEF truncations can indeed be toxic in both yeast and mammalian cell models and may directly contribute to ALS pathogenesis.
Protein folding stress in the endoplasmic reticulum (ER) is implicated in many neurodegenerative disorders, including ALS. Several regions of RGNEF are predicted to be intrinsically disordered, which can contribute to its misfolding and inclusion formation, particularly in environmental stress. These results demonstrate that ER stress exacerbates RGNEF toxicity suggesting that proper folding of RGNEF is required for proper function. Furthermore, our split-ubiquitin screen identified the Sigma receptor 1 (Sigmar1) as an RGNEF interactor. An ALS-associated mutation in the gene encoding Sigmar1 causes rapid aggregation of the protein in the ER leading to proteotoxic stress and impaired autophagy, accumulation of stress granules and cytoplasmic aggregation of the ALS proteins TDP-43, FUS and Matrin3 (Dreser et al.). While the precise mechanisms are still undefined, it is plausible that Sigmar1 links ER stress to RGNEF toxicity.

The split-ubiquitin screen and genetic and microscopic experiments identified microtubule regulators as the largest functional group of protein RGNEF interactors. ALS is characterized by the degeneration of motor neurons, their axons and synapses, highlighting the importance of maintaining the axonal transport systems built by microtubules (Griffin and Watson, 1988, Sleigh et al., 2019). Also, mutation of the microtubule subunit TUB4A causes rare forms of fALS and there is evidence of microtubule dysfunction and collapse in both sALS and fALS (Smith et al., 2014). The murine homolog of RGNEF, p190RhoGEF, stabilizes the mRNA of NEFL (low molecular weight neurofilaments) (Volkening et al., 2010). This finding links the RNA binding capacity of RGNEF to the direct interaction with microtubule subunits and microtubule regulators. We identified TUB4A as an RGNEF interactor. In addition, we found that genetic deletion of some microtubule regulators greatly modified RGNEF toxicity in the yeast model. Accordingly, RGNEF may interact with microtubules and regulate their function. We also found that small molecule-induced disruption of microtubules exacerbates RGNEF toxicity and treatment of Neuro 2A cells with nocodazole or colchicine induced the formation of RGNEF inclusions. Taken together, these findings suggest a functional link between RGNEF and the microtubule network that may be compromised by RGNEF misfolding and aggregation in ALS.

Collectively, our study indicates that RGNEF can contribute to cytotoxicity either alone or in combination with other ALS proteins, and impairing the proper function of the microtubule network. Future studies will need to clarify the underlying molecular mechanisms and the exact contributions of RGNEF and the smaller forms of RGNEF predicted to arise from ALS mutations to the pathogenesis of ALS.

Materials and Methods

Materials

All chemicals were purchased from Sigma-Aldrich and VWR. S. cerevisiae were grown on plates and in liquid media containing all essential nutrients aside from amino acids required to maintain plasmid selectivity, and 2% (w/v) glucose or galactose under induced and non-induced conditions (Weinhandl et al., 2014).

All yeast strains are W303 Mat a or BY Mat α background and their derivatives (Table 1). All gene deletion strains are in the BY Mat a background obtained from gene deletion library (Thomas and Rothstein, 1989).

Plasmids for mammalian cell transfection were generated using Gateway cloning technology as previously described (Invitrogen) (Katzen, 2007). Split-ubiquitin fusions very engineered by restriction digest and ligation-based cloning. DNA templates, pcDNA-RGNEF-myc and pcDNA-ΔGEF-RGNEF-myc, for the generation of all constructs used in this study were generously provided by Dr. Cristian Droppelmann.

HEK 293, Neuro2A and SNC-34 cell lines were grown in DMEM (4g/L glucose), or DMEM (1g/L glucose) (Gibco) and supplemented with 10% Bovine serum (Wisent), Pen/strep (Gibco), and 1% L-glutamine (Gibco). Cells were detached with 5% Trypsin (Gibco). All wash steps were carried out using cell culture grade PBS (Gibco). Lipofectamine® 2000 (Invitrogen) was used for transfections according to the manufacturer’s instructions.
Methods:

Yeast Transformations

Yeast strains were transformed using the LiAc procedure as previously described (Gietz, 2014). Cells were inoculated overnight in 3ml YPD and allowed to grow to saturation. The following morning, cultures were switched to 27ml YPD and allowed to grow to an OD600 of 0.4. Cells were washed twice in sterile water and suspended in 10M LiAc solution for 30 minutes at 30°C. Cells were then centrifuged and resuspended in LiAc, 50% PEG, DMSO, ss DNA carrier, and DNA and heat-shocked for 20 minutes at 42°C. Then, cells were re-suspended in 1x Tris EDTA buffer and plated on selective agar plates (non-induced conditions). Transformation plates were placed at 30°C for three days and colonies were chosen and streaked (4 biologicals/transformation) and allowed to grow for three days. Selection by amino acid exclusion was maintained.

Spotting Assays

Yeast strains were inoculated overnight in 3ml of selective growth media at 30°C and grown to saturation. The optical density (OD600) was measured for each strain following 16h of growth. Cultures were transferred to the top wells of sterile 96-well plates (Greiner bio-one #650161) and normalized to a starting OD600 of 0.1 in 200ul. A five-fold serial dilution was performed using a multichannel pipette to transfer 30ul of the normalized cultures into 120ul of water. Cells were transferred to single agar plates using a sterilized 48-pin “replicate-plater”. Cells were spotted on non-inducing, overgrowth controls and inducing, selective plates. In the case of chemical treatments, cells were plated on agar plates containing the indicated concentration of various canonical stressors (50uM MG132, 100uM H202, 25uM Radicicol, 1ug/ml Tunicamycin, 5mM DTT, 500nM Colchicine, 500nM Nocodazole).

Quantification

For quantification, plates with yeast spotting assays were photographed on Bio-Rad GelDoc system. Images were first processed in Photoshop to remove color data and converted into black and white images. Images were then imported into ImageJ for quantification. A circular measuring tool was fit to the size of the third dilution and the white pixels were counted for each condition. Background was also measured and subtracted from each data point. Measured values were input into GraphPad prism to generate bar graphs. Statistical analysis was carried out on both normalized and unadjusted data applying One Way Analysis of Variance, Tukey Post Hok using IBM SPSS. Error bars represent standard errors.

Split Ubiquitin Interaction Assay

Split-Ub expression clones were generated using standard restriction- and ligation-based cloning. RGNEF (bait) fused to the C-terminal half of Ubiquitin and the Ura3 reporter was probed against a prey library fused to the N-terminus of Ubiquitin. RGNEF, TDP-43, and PGK1 fused to the N-terminus of Ubiquitin with different point mutations (Isoleucine, Alanine, Glycine), were generated and used in directed screens. Strains were generated expressing both the bait and prey constructs and plated on plates containing 500uM CuSO4 and 5FOA (positive selection media), and plates containing uracil and 5FOA (negative selection media), and on YPD (overgrowth control). Colonies were isolated and DNA extracted following overnight incubation in selective media using the Zymoprep yeast plasmid miniprep kit (ZYMO). DNA was sequenced using primers against the N-terminus of ubiquitin. Genes were identified by sequence comparison using BLAST.

Microscopy

Yeast strains were inoculated in 3ml of non-inducing media and allowed to grow overnight at 30°C. The following evening, cultures were spun and washed twice in water, then resuspended in inducing growth media and returned to 30°C for overnight growth. Following a minimum of 16
hours induction, yeast cells were pipetted onto glass slides and sealed under coverslips using nail-polish. Fluorescence microscopy was performed using the Cytation5 cell imaging multi-mode reader (BioTek). The following LED cubes and imaging filter cubes from biotech were employed for GFP tagged proteins: 465 LED 1225001 Rev J, GFP 469/525 1225101 Rev J, BioTek; and for CFP tagged proteins: 465 LED 1225001 Rev J, CFP 445/510 1225107 Rev J. Images were captured on the 20x objective. Image analysis was completed using the Gen5 imaging software (BioTek).

Yeast microscopy data was quantified by taking three biological fields on the 20x objective and overlaying a grid to cut the image into four quadrants. 50 cells were counted and sorted as either showing a diffuse signal or containing one or more fluorescent foci for each biological. Stacked bar graphs with SD error bars were generated in GraphPad Prism using this data.

Mammalian cell culture

Mammalian cells used include human (HeLa, HEK 293), and mouse derived (Neuro2a, NSC-34) lines. All lines were grown in DMEM, 5% bovine serum in the presence of pen/strep. All cells were cultured at 37°C in the presence of 5% CO2. Partial differentiation of Neuro2a and NSC-34 cells was carried out by growing cells for three days in DMEM in the absence of bovine serum. Transfection of pcDNA 3.1 GFP RGNEF WT, ∆Cterm and ∆Leu was carried out with Lipofectamine® 2000 as described previously (Invitrogen 11668030) in Opti-MEM™ reduced serum media (Gibco™ 31985062).

Immunofluorescence Microscopy

HEK293 cells were seeded at 1,250 cells/well in 96 white well plates and transfected as stated above. The Cell Titer Glo 2.0 (Promega), and the luciferase based luminescence viability assay was used to detect viable cells. Luminescence was measured on Cytation5 plate reader (BioTek).

Prior to imaging, cells were seeded at 2,500 cells/well in Nunc, 8 well chamber slides in DMEM, 5% or 0% bovine serum. Media was removed and replaced with growth medium containing the indicated chemical concentrations. Control wells were replaced with the same growth media lacking any additional treatment. Following treatment, media was aspirated and cells were probed with anti-RGNEF (abcam ab122399), and anti-Tubulin (abcam ab4074) overnight. Primary antibody solution was aspirated and cells were washed in PBS and incubated with Alexa Fluor 488 and Alexa Fluor 688 secondary antibodies (Thermo-Fischer Scientific) for one hour. Cells were fixed to the slide using 30% paraformaldehyde. ProLong Diamond antifade mounting solution (Thermo-Fischer Scientific, P36965), was added to fixed cells and covered by a coverslip. Slides were sealed with clear nail polish.

Fluorescence microscopy was performed using the Cytation5 cell imaging multi-mode reader (BioTek). The following LED cubes and imaging filter cubes from biotech were employed for RGNEF probed with Alexa Fluor 488 secondary: 465 LED 1225001 Rev J, GFP 469/525 1225101 Rev J, BioTek); for tubulin probed with Alexa Fluor 688: TEXAS RED 586/647, 1225 102 Rev H. Images were captured on the 20x objective. Image analysis was completed using the Gen5 imaging software (BioTek).

Summary Statement

We have characterised a novel yeast model expressing human RGNEF, a protein implicated in amyotrophic lateral sclerosis. Using this yeast model and mammalian cells we have shown that overexpressed RGNEF forms inclusions, is cytotoxic, and is sensitive to cellular stress. We also uncovered a potential role for RGNEF as a microtubule regulator.

Acknowledgments: We would like to thank Dr. Cristian Droppelmann for providing the RGNEF vectors.

Competing Interests: The authors declare no competing interests.

Funding: ALS Canada Bernice Ramsey Research Grant to MLD, KV, and MJS, ALS Canada Doctoral Fellowship to SED.
Author Contributions statement: All experiments were conducted by SED. Experimental design was conducted by MD. Analyses of data was conducted by MD, SED and data interpretations by SED, KV, MJS, and MLD. Manuscript preparation, editing and proofreading was conducted by MD, SED, KV, and MJS.

References:

ALLINGHAM, J. S., SPROUL, L. R., RAYMENT, I. & GILBERT, S. P. 2007. Vik1 modulates microtubule-Kar3 interactions through a motor domain that lacks an active site. Cell, 128, 1161-72.

BALIKOVA, I., DEVRIENDT, K., FRYNS, J. P. & VERMEESCH, J. R. 2010. FOXD1 Duplication Causes Branchial Defects and Interacts with the TFAP2A Gene Implicated in the Branchio-Oculo-Facial Syndrome in Causing Eye Effects in Zebrafish. Mol Syndromol, 1, 255-261.

BARBER, S. C., MEAD, R. J. & SHAW, P. J. 2006. Oxidative stress in ALS: a mechanism of neurodegeneration and a therapeutic target. Biochim Biophys Acta, 1762, 1051-67.

CANNON, J. R. & GREENAMYRE, J. T. 2011. The role of environmental exposures in neurodegeneration and neurodegenerative diseases. Toxicol Sci, 124, 225-50.

CHEN, S., SAYANA, P., ZHANG, X. & LE, W. 2013. Genetics of amyotrophic lateral sclerosis: an update. Mol Neurodegener.

CHEUNG, K., DROPPELMANN, C. A., MACLELLAN, A., CAMERON, I., WITHERS, B., CAMPOS-MELO, D., VOLKENING, K. & STRONG, M. J. 2017. Rho guanine nucleotide exchange factor (RGNEF) is a prosurvival factor under stress conditions. Mol Cell Neurosci, 82, 88-95.

DI GREGORIO, S. E. & DUENNWALD, M. L. 2018. ALS Yeast Models-Past Success Stories and New Opportunities. Front Mol Neurosci, 11, 394.

DRESER, A., VOLLRATH, J. T., SECHI, A., JOHANN, S., ROOS, A., YAMOAH, A., KATONA, I., BOHEGA, S., WIEMUTH, D., TIAN, Y., SCHMIDT, A., VERVOORTS, J., DOHMEN, M., BEYER, C., ANINK, J., ARONICA, E., TROOST, D., WEIS, J. & GOSWAMI, A. The ALS-linked E102Q mutation in Sigma receptor-1 leads to ER stress-mediated defects in protein homeostasis and dysregulation of RNA-binding proteins.

DROPPELMANN, C. A., CAMPOS-MELO, D., MOSZCZYNSKI, A. J., AMZIL, H. & STRONG, M. J. 2019. TDP-43 aggregation inside micronuclei reveals a potential mechanism for protein inclusion formation in ALS. Sci Rep, 9, 19928.

DROPPELMANN, C. A., CAMPOS-MELO, D., VOLKENING, K. & STRONG, M. J. 2014. The emerging role of guanine nucleotide exchange factors in ALS and other neurodegenerative diseases. Front Cell Neurosci, 8, 282.

DROPPELMANN, C. A., KELLER, B. A., CAMPOS-MELO, D., VOLKENING, K. & STRONG, M. J. 2013a. Rho guanine nucleotide exchange factor is an NFL mRNA destabilizing factor that forms cytoplasmic inclusions in amyotrophic lateral sclerosis. Neurobiol Aging, 34, 248-62.

DROPPELMANN, C. A., WANG, J., CAMPOS-MELO, D., KELLER, B., VOLKENING, K., HEGELE, R. A. & STRONG, M. J. 2013b. Detection of a novel frameshift mutation and regions with homozygosis within ARHGEF28 gene in familial amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener, 14, 444-51.

FARHAN, S. M. K., GENDRON, T. F., PETRUCELLI, L., HEGELE, R. A. & STRONG, M. J. 2017. ARHGEF28p.Lys280Metfs40Ter in an amyotrophic lateral sclerosis family with a C9orf72 expansion. Neurol Genet, 3, e190.

GIETZ, R. D. 2014. Yeast transformation by the LiAc/SS carrier DNA/PEG method. Methods Mol Biol, 1163, 33-44.
GITLER, A. D. & FRYER, J. D. 2018. A matter of balance. *Elife*, 7.

GITLER, A. D. & SHORTER, J. 2011. RNA-binding proteins with prion-like domains in ALS and FTLD-U. *Prion*, 5, 179-87.

GRIFFIN, J. W. & WATSON, D. F. 1988. Axonal transport in neurological disease. *Ann Neurol*, 23, 3-13.

HARDIMAN, O., AL-CHALABI, A., CHIO, A., CORR, E. M., LOGROSCINO, G., ROBBERECHT, W., SHAW, P. J., SIMMONS, Z. & VAN DEN BERG, L. H. 2017. Amyotrophic lateral sclerosis. *Nat Rev Dis Primers*, 3, 17071.

HOEBEKE, J., VAN NIJEN, G. & DE BRABANDER, M. 1976. Interaction of oncodazole (R 17934), a new antitumoral drug, with rat brain tubulin. *Biochem Biophys Res Commun*, 69, 319-24.

JOHNSSON, N. & VARSHAVSKY, A. 1994. Split ubiquitin as a sensor of protein interactions in vivo. *Proc Natl Acad Sci U S A*, 91, 10340-4.

KATZEN, F. 2007. Gateway((R)) recombinational cloning: a biological operating system. *Expert Opin Drug Discov*, 2, 571-89.

KELLER, B. A., VOLKENING, K., DROPPELMANN, C. A., ANG, L. C., RADEMAKERS, R. & STRONG, M. J. 2012. Co-aggregation of RNA binding proteins in ALS spinal motor neurons: evidence of a common pathogenic mechanism. *Acta Neuropathol*, 124, 733-47.

KIKIS, E. A., GIDALEVITZ, T. & MORIMOTO, R. I. 2010. Protein homeostasis in models of aging and age-related conformational disease. *Adv Exp Med Biol*, 694, 138-59.

KIRSCH-VOLDERS, M., ELHAJOUJI, A., CUNDARI, E. & VAN HUMMELEN, P. 1997. The in vitro micronucleus test: a multi-endpoint assay to detect simultaneously mitotic delay, apoptosis, chromosome breakage, chromosome loss and non-disjunction. *Mutat Res*, 392, 19-30.

KLEINSCHMIDT, E. G., MILLER, N. L. G., OZMADENCI, D., TANCIONI, I., OSTERMAN, C. D., BARRIE, A. M., TAYLOR, K. N., YE, A., JIANG, S., CONNOLLY, D. C., STUPACK, D. G. & SCHLAEPFER, D. D. 2019. Rgnef promotes ovarian tumor progression and confers protection from oxidative stress. *Oncogene*, 38, 6323-6337.

KRYNDUSHKIN, D. & SHEWMAKER, F. 2011. Modeling ALS and FTLD proteinopathies in yeast: an efficient approach for studying protein aggregation and toxicity. *Prion*, 5, 250-7.

LEHMING, N. 2002. Analysis of protein-protein proximities using the split-ubiquitin system. *Brief Funct Genomic Proteomic*, 1, 230-8.

LEUNG, Y. Y., YAO HUI, L. L. & KRAUS, V. B. 2015. Colchicine--Update on mechanisms of action and therapeutic uses. *Semin Arthritis Rheum*, 45, 341-50.

MA, Y., TANG, L., CHEN, L., ZHANG, B., DENG, P., WANG, J., YANG, Y., LIU, R., YE, S., LIU, X., ZHANG, H. & FAN, D. 2014. ARHGEF28 gene exon 6/intron 6 junction mutations in Chinese amyotrophic lateral sclerosis cohort. *Amyotroph Lateral Scler Frontotemporal Degen*, 15, 309-11.

MASIA-BALAGUE, M., IZQUIERDO, I., GARRIDO, G., CORDOMI, A., PEREZ-BENITO, L., MILLER, N. L., SCHLAEPFER, D. D., GIGOUX, V. & ARAGAY, A. M. 2015. Gastrin-stimulated Galpha13 Activation of Rgnef Protein (ArhGEF28) in DLD-1 Colon Carcinoma Cells. *J Biol Chem*, 290, 15197-209.

MILLER, N. L., LAWSON, C., CHEN, X. L., LIM, S. T. & SCHLAEPFER, D. D. 2012. Rgnef (p190RhoGEF) knockout inhibits RhoA activity, focal adhesion establishment, and cell motility downstream of integrins. *PLoS One*, 7, e37830.

MILLER, R. K., HELLER, K. K., FRISEN, L., WALLACK, D. L., LOAYZA, D., GAMMIE, A. E. & ROSE, M. D. 1998. The kinesin-related proteins, Kip2p and Kip3p, function differently in nuclear migration in yeast. *Mol Biol Cell*, 9, 2051-68.
MULLER, J. & JOHNSSON, N. 2008. Split-ubiquitin and the split-protein sensors: chessman for the endgame. *Chembiochem*, 9, 2029-38.

PARAKH, S. & ATKIN, J. D. 2016. Protein folding alterations in amyotrophic lateral sclerosis. *Brain Res*, 1648, 633-649.

PATEL, A., LEE, H. O., JAWERTH, L., MAHARANA, S., JAHNEL, M., HEIN, M. Y., STOYNOV, S., MAHAMID, J., SAHA, S., FRANZMANN, T. M., POZNIAKOVSKI, A., POSER, I., MAGHELLI, N., ROYER, L. A., WEIGERT, M., MYERS, E. W., GRILL, S., DRECHSEL, D., HYMAN, A. A. & ALBERTI, S. 2015. A Liquid-to-Solid Phase Transition of the ALS Protein FUS Accelerated by Disease Mutation. *Cell*, 162, 1066-77.

REDLER, R. L. & DOKHOLYAN, N. V. 2012. The complex molecular biology of amyotrophic lateral sclerosis (ALS). *Prog Mol Biol Transl Sci*, 107, 215-62.

SABERI, S., STAUFFER, J. E., SCHULTE, D. J. & RAVITS, J. 2015. Neuropathology of Amyotrophic Lateral Sclerosis and Its Variants. *Neurol Clin*, 33, 855-76.

SCHMID, W. The micronucleous test for cytogenetic analysis.

SCHUYLER, S. C., LIU, J. Y. & PELLMAN, D. 2003. The molecular function of Ase1p: evidence for a MAP-dependent midzone-specific spindle matrix. *Microtubule-associated proteins. J Cell Biol*, 160, 517-28.

SLEIGH, J. N., ROSSOR, A. M., FELLOWS, A. D., TOSOLINI, A. P. & SCHIAVO, G. 2019. Axonal transport and neurological disease. *Nat Rev Neurol*, 15, 691-703.

SMITH, B. N., TICOZZI, N., FALLINI, C., GKAZI, A. S., TOPP, S., KENNA, K. P., SCOTTER, E. L., KOST, J., KEAGLE, P., MILLER, J. W., CALINI, D., VANCE, C., DANIELSON, E. W., TROAKES, C., TILoca, C., AL-SARRAJ, S., LEWIS, E. A., KING, A., COLOMBRITA, C., PENSAO, V., CASTELLOTTI, B., DE BELLEROCHE, J., BAAS, F., TEN ASBROEK, A. L., SAPP, P. C., MCKENNA-YASEK, D., MCLAUGHLIN, R. L., POLAK, M., ASRESS, S., ESTEBAN-PEREZ, J., MUÑOZ-BLANCO, J. L., SIMPSON, M., VAN RHEENEN, W., DIEKSTRA, F. P., LAURIA, G., DUGA, S., CORTI, S., CEREDA, C., CORRADO, L., SORARU, G., MORRISON, K. E., WILLIAMS, K. L., NICHOLSON, G. A., BLAIR, I. P., DION, P. A., LEBLOND, C. S., ROULEAU, G. A., HARDIMAN, O., VELDINK, J. H., VAN DEN BERG, L. H., AL-CHALABI, A., PALL, H., SHAW, P. J., TURNER, M. R., TALBOT, K., TARONI, F., GARCIA-REDONDO, A., WU, Z., GLASS, J. D., GELLERA, C., RATTI, A., BROWN, R. H., JR., SILANI, V., SHAW, C. E. & LANDERS, J. E. 2014. Exome-wide rare variant analysis identifies TUBA4A mutations associated with familial ALS. *Neuron*, 84, 324-31.

SOTO, C. 2003. Unfolding the role of protein misfolding in neurodegenerative diseases. *Nat Rev Neurosci*, 4, 49-60.

SOTO, C. & ESTRADA, L. D. 2008. Protein misfolding and neurodegeneration. *Arch Neurol*, 65, 184-9.

SRINIVASAN, E. & RAJASEKARAN, R. 2020. A Systematic and Comprehensive Review on Disease-Causing Genes in Amyotrophic Lateral Sclerosis. *J Mol Neurosci*.

TAVOLIERI, M. V., DROPPELMANN, C. A., CAMPOS-MELO, D., VOLKENING, K. & STRONG, M. J. 2019. A novel overlapping NLS/NES region within the PH domain of Rho Guanine Nucleotide Exchange Factor (RGNEF) regulates its nuclear-cytoplasmic localization. *Eur J Cell Biol*, 98, 27-35.

TENREIRO, S., FRANSESSENS, V., WINDERICKX, J. & OUTEIRO, T. F. 2017. Yeast models of Parkinson’s disease-associated molecular pathologies. *Curr Opin Genet Dev*, 44, 74-83.

TENREIRO, S., MUNDER, M. C., ALBERTI, S. & OUTEIRO, T. F. 2013. Harnessing the power of yeast to unravel the molecular basis of neurodegeneration. *J Neurochem*, 127, 438-52.
TENREIRO, S. & OUTEIRO, T. F. 2010. Simple is good: yeast models of neurodegeneration. *FEMS Yeast Res*, 10, 970-9.

THOMAS, B. J. & ROTHSTEIN, R. 1989. Elevated recombination rates in transcriptionally active DNA. *Cell*, 56, 619-30.

VAN HAM, T. J., BREITLING, R., SWERTZ, M. A. & NOLLEN, E. A. A. 2009. Neurodegenerative diseases: Lessons from genome-wide screens in small model organisms. *EMBO Mol Med*, 1, 360-70.

VAN HORCK, F. P., AHMADIAN, M. R., HAEUSLER, L. C., MOOLENAAR, W. H. & KRANENBURG, O. 2001. Characterization of p190RhoGEF, a RhoA-specific guanine nucleotide exchange factor that interacts with microtubules. *J Biol Chem*, 276, 4948-56.

VOLKENING, K., LEYSTRA-LANTZ, C. & STRONG, M. J. 2010. Human low molecular weight neurofilament (NFL) mRNA interacts with a predicted p190RhoGEF homologue (RGNEF) in humans. *Amyotroph Lateral Scler*, 11, 97-103.

WEINHANDL, K., WINKLER, M., GLIEDER, A. & CAMATTARI, A. 2014. Carbon source dependent promoters in yeasts. *Microb Cell Fact*.

WU, J., ZHAI, J., LIN, H., NIE, Z., GE, W. W., GARCIA-BERMEJO, L., MUSCHEL, R. J., SCHLAEPFER, W. W. & CANETE-SOLER, R. 2003. Cytoplasmic retention sites in p190RhoGEF confer anti-apoptotic activity to an EGFP-tagged protein. *Brain Res Mol Brain Res*, 117, 27-38.

YU, H. G., NAM, J. O., MILLER, N. L., TANJONI, I., WALSH, C., SHI, L., KIM, L., CHEN, X. L., TOMAR, A., LIM, S. T. & SCHLAEPFER, D. D. 2011. p190RhoGEF (Rgnef) promotes colon carcinoma tumor progression via interaction with focal adhesion kinase. *Cancer Res*, 71, 360-70.

ZHENG, Y., HART, M. J., SHINJO, K., EVANS, T., BENDER, A. & CERIONE, R. A. 1993. Biochemical comparisons of the Saccharomyces cerevisiae Bem2 and Bem3 proteins. Delineation of a limit Cdc42 GTPase-activating protein domain. *J Biol Chem*, 268, 24629-34.